Clinical Trial Detail

NCT ID NCT02504489
Title Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC (DUBLIN-3)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors BeyondSpring Pharmaceuticals Inc.
Indications

lung non-small cell carcinoma

Therapies

Docetaxel

Docetaxel + Plinabulin

Age Groups: senior adult

Additional content available in CKB BOOST